Therefore, our automatic IL6/IL1 blockade platform serves as a promising strategy to minimize IL6/IL1-associated cytokine toxicity and neurotoxiticy for future development of new target directed CART therapy against hematologic malignancy, or gene edited production of off-shelf allogeneic CART cells. This evidence concerns the gene IL6 and hematologic disorder.